MYC and breast carcinoma: Indeed, research has shown when Mel was used as an adjuvant for arsenic trioxide treatment, it inhibits the growth of breast cancer cells via inducing p21 expression, leading to G1 cell cycle arrest and suppression of human telomerase reverse transcriptase and proto‐oncogene Myc protein.43 Additionally, a new study has shown that Mel treatment effectively down‐regulated miR‐24, an important oncogenic miRNA which reduces the activity of the p38‐p53 axis components.